Targeted drug shows promise for Hard-to-Treat lung cancer
NCT ID NCT06933329
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests an experimental drug, zelenectide pevedotin, in people with advanced non-small cell lung cancer that has a specific genetic change (NECTIN4 amplification) and has already been treated with at least one prior therapy. The goal is to see if the drug can shrink tumors and to check its safety. About 73 participants will receive the drug in an open-label design.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario Universitario A Coruña
A Coruña, 15006, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.